Daiichi Sankyo Hauls Back Mid-Term Profit Outlook As It Builds Oncology
Executive Summary
Big cut in mid-term profit outlook hits Daiichi Sankyo shares but company says it is reallocating more to R&D to accelerate the strategic build-out of its oncology franchise.
You may also be interested in...
Oncology Deal-Making The Daiichi Way
Daiichi Sankyo’s relatively young strategic pivot into oncology is paying major dividends, with two huge global deals with AstraZeneca now in the bag within 18 months. Scrip takes a closer look with the help of insights from the Japanese firm’s global oncology R&D head.
Penalty For Daiichi As It Falls Short In Japan Flu Vaccine Project
Japanese firm fails to meet production capacity target under Japan national flu vaccine supply plan, triggering a financial penalty and the return of government grant money.
Keeping Track Of Oncology: US FDA Approves Herceptin Hylecta, Reviews Darolutamide And Pexidartinib
Oncology news and highlights from our US FDA Performance Tracker.